Dr Holly Holliday

Dr Holly Holliday

Conjoint Lecturer

Aug 2014 – Dec 2018        PhD, The Garvan Institute of Medical Research and UNSW Sydney, Australia.

Feb 2010 – Nov 2013        BMedSci, Hons I and University Medal, Major in Biochemistry, USYD.

Medicine & Health
School of Clinical Medicine

Dr Holly Holliday is a Cancer Institute NSW Early Career Fellow in the Brain Tumour Group (PI Prof David Ziegler) at the Children’s Cancer Institute. She is a cell and molecular biologist with expertise in epigenetics, gene regulation, and paediatric cancer. Dr. Holliday completed a Bachelor of Medical Science, majoring in Biochemistry, from the University of Sydney in 2014. She completed her PhD at the Garvan Institute, where she investigated transcriptional regulation in mammary gland development. Her early postdoctoral research at the Garvan Institute focused on the role of microRNAs in neuroblastoma. Currently, Dr. Holliday’s research centres on developing epigenetic therapies for highly aggressive, epigenetic-driven paediatric high-grade gliomas. Her work includes targeting the FACT histone chaperone and other epigenetic regulators, such as BET proteins and PAD enzymes. In addition, she investigates tumour-microenvironment interactions using advanced spatial profiling technologies in patient specimens and mouse models.

Location
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia Randwick 2031 Australia
  • Journal articles | 2024
    Holliday H; Khan A; Jayatilleke N; Mayoh C; Ross SE; Guo X; Sanguino YC; Gopalakrishnan A; Ehteda A; Tsoli M; Ziegler DS, 2024, 'COMBINED EPIGENETIC THERAPY WITH FACT AND BET INHIBITORS REMODELS CHROMATIN AND DISRUPTS ONCOGENIC TRANSCRIPTION IN DIFFUSE MIDLINE GLIOMA', NEURO-ONCOLOGY, 26, http://dx.doi.org/10.1093/neuonc/noae064.077
    Journal articles | 2024
    Holliday H; Khan A; Jayatilleke N; Mayoh C; Ross SE; Sanguino YC; Gopalakrishnan A; Ehteda A; Rayner B; Tsoli M; Ziegler DS, 2024, 'Targeting the epigenome through combined Facilitates Chromatin Transcription (FACT) and Bromodomain and Extra-Terminal Domain (BET) inhibition in Diffuse Midline Glioma (DMG)', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.BRAIN23-B016
    Journal articles | 2024
    Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2024, 'Erratum: miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma (Molecular Therapy (2022) 30(3) (1119–1134), (S1525001622000041), (10.1016/j.ymthe.2022.01.004))', Molecular Therapy, 32, pp. 2031 - 2033, http://dx.doi.org/10.1016/j.ymthe.2024.05.008
    Journal articles | 2024
    Pereira BA; Ritchie S; Chambers CR; Gordon KA; Magenau A; Murphy KJ; Nobis M; Tyma VM; Liew YF; Lucas MC; Naeini MM; Barkauskas DS; Chacon-Fajardo D; Howell AE; Parker AL; Warren SC; Reed DA; Lee V; Metcalf XL; Lee YK; O'Regan LP; Zhu J; Trpceski M; Fontaine ARM; Stoehr J; Rouet R; Lin X; Chitty JL; Porazinski S; Wu SZ; Filipe EC; Cadell AL; Holliday H; Yang J; Papanicolaou M; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Vennin C; Yin J; Dew AB; McMillan PJ; Goldstein LD; Deveson IW; Croucher DR; Samuel MS; Sim HW; Batten M; Chantrill L; Grimmond SM; Gill AJ; Samra J; Jeffry Evans TR; Sasaki T; Phan TG; Swarbrick A; Sansom OJ; Morton JP; Pajic M; Parker BL; Herrmann D; Cox TR; Timpson P, 2024, 'Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response', Science Advances, 10, http://dx.doi.org/10.1126/sciadv.adl1197
    Journal articles | 2024
    Rayner BS; Samadder A; Holliday H; Chen Y; Nguyen H; Lee A; Liu J; Hayden E; Ogunmodede OS; Rye K-A; Tsoli M; Bertoldo JB; Ziegler DS, 2024, 'THE BIG AND SMALL OF PROTEIN POST-TRANSLATIONAL MODIFICATIONS: TARGETING SUMOYLATION AND CITRULLINATION IN DIFFUSE MIDLINE GLIOMA', NEURO-ONCOLOGY, 26, http://dx.doi.org/10.1093/neuonc/noae064.069
    Journal articles | 2024
    Ross SE; Holliday H; Tsoli M; Ziegler DS; Dinger ME, 2024, 'Abstract B015: RNA N6-methyladenosine (m6A) as a therapeutic target in Diffuse Midline Glioma (DMG)', Cancer Research, 84, pp. B015 - B015, http://dx.doi.org/10.1158/1538-7445.brain23-b015
    Journal articles | 2023
    Glover HJ; Holliday H; Shparberg RA; Winkler D; Day M; Morris MB, 2023, 'Signalling pathway crosstalk stimulated by L-proline drives mouse embryonic stem cells to primitive-ectoderm-like cells', Development (Cambridge), 150, http://dx.doi.org/10.1242/dev.201704
    Journal articles | 2023
    Thai LM; O'Reilly L; Reibe-Pal S; Sue N; Holliday H; Small L; Schmitz-Peiffer C; Dhenni R; Wang-Wei Tsai V; Norris N; Yau B; Zhang X; Lee K; Yan C; Shi YC; Kebede MA; Brink R; Cooney GJ; Irvine KM; Breit SN; Phan TG; Swarbrick A; Biden TJ, 2023, 'β-cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving Axl, Mertk, and TGFβ receptor signaling', iScience, 26, http://dx.doi.org/10.1016/j.isci.2023.106477
    Journal articles | 2022
    Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2022, 'miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma', Molecular Therapy, 30, pp. 1119 - 1134, http://dx.doi.org/10.1016/j.ymthe.2022.01.004
    Journal articles | 2021
    Hayden E; Holliday H; Lehmann R; Khan A; Tsoli M; Rayner BS; Ziegler DS, 2021, 'Therapeutic targets in diffuse midline gliomas—an emerging landscape', Cancers, 13, http://dx.doi.org/10.3390/cancers13246251
    Journal articles | 2021
    Holliday H; Khoury A; Swarbrick A, 2021, 'Chromatin immunoprecipitation of transcription factors and histone modifications in Comma-Dβ mammary epithelial cells', STAR Protocols, 2, http://dx.doi.org/10.1016/j.xpro.2021.100514
    Journal articles | 2021
    Holliday H; Roden D; Junankar S; Wu SZ; Baker LA; Krisp C; Chan CL; McFarland A; Skhinas JN; Cox TR; Pal B; Huntington ND; Ormandy CJ; Carroll JS; Visvader J; Molloy MP; Swarbrick A, 2021, 'Inhibitor of Differentiation 4 (ID4) represses mammary myoepithelial differentiation via inhibition of HEB', iScience, 24, http://dx.doi.org/10.1016/j.isci.2021.102072
    Journal articles | 2021
    McEvoy CR; Holliday H; Thio N; Mitchell C; Choong DY; Yellapu B; Leong HS; Xu H; Lade S; Browning J; Takano EA; Byrne DJ; Gill AJ; Duong CP; Li J; Fellowes AP; Fox SB; Swarbrick A; Prall OWJ, 2021, 'A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors', Laboratory Investigation, 101, pp. 26 - 37, http://dx.doi.org/10.1038/s41374-020-00484-3
    Journal articles | 2021
    McEvoy CR; Holliday H; Thio N; Mitchell C; Choong DY; Yellapu B; Leong HS; Xu H; Lade S; Browning J; Takano EA; Byrne DJ; Gill AJ; Duong CP; Li J; Fellowes AP; Fox SB; Swarbrick A; Prall OWJ, 2021, 'A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors.', Lab Invest, 101, pp. 26 - 37, http://dx.doi.org/10.1038/s41374-020-00484-3
    Journal articles | 2020
    Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, 'Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01306-6
    Journal articles | 2020
    Holliday H; Roden D; Junankar S; Wu S; Baker L; Krisp C; Chan C-L; McFarland A; Skhinas J; Cox T; Pal B; Huntington N; Ormandy C; Carroll J; Visvader J; Molloy M; Swarbrick A, 2020, 'Inhibitor of Differentiation 4 (ID4) represses myoepithelial differentiation of mammary stem cells through its interaction with HEB', , http://dx.doi.org/10.1101/2020.04.06.026963
    Journal articles | 2020
    Teo WS; Holliday H; Karthikeyan N; Cazet AS; Roden DL; Harvey K; Konrad CV; Murali R; Varghese BA; Thankamony AP; Chan CL; McFarland A; Junankar S; Ye S; Yang J; Nikolic I; Shah JS; Baker LA; Millar EKA; Naylor MJ; Ormandy CJ; Lakhani SR; Kaplan W; Mellick AS; O'Toole SA; Swarbrick A; Nair R, 2020, 'Id Proteins Promote a Cancer Stem Cell Phenotype in Mouse Models of Triple Negative Breast Cancer via Negative Regulation of Robo1', Frontiers in Cell and Developmental Biology, 8, http://dx.doi.org/10.3389/fcell.2020.00552
    Journal articles | 2020
    Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R, 2020, 'Targeting the id1-kif11 axis in triple-negative breast cancer using combination therapy', Biomolecules, 10, pp. 1 - 15, http://dx.doi.org/10.3390/biom10091295
    Journal articles | 2020
    Wu S; Roden D; Wang C; Holliday H; Harvey K; Cazet A; Murphy K; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy J; Junankar S; Chan C-L; Lam E; Hui M; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O’Toole S; Cox T; Timpson P; Lim E; Liu S; Swarbrick A, 2020, 'Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135327
    Journal articles | 2020
    Wu SZ; Roden DL; Wang C; Holliday H; Harvey K; Cazet AS; Murphy KJ; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy JR; Junankar S; Chan CL; Lam CE; Hui MN; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O'Toole S; Cox TR; Timpson P; Lim E; Liu XS; Swarbrick A, 2020, 'Stromal cell diversity associated with immune evasion in human triple-negative breast cancer', EMBO Journal, 39, pp. embj2019104063, http://dx.doi.org/10.15252/embj.2019104063
    Journal articles | 2018
    Baker L; Krisp C; Roden D; Holliday H; Wu S; Junankar S; Serandour A; Mohammed H; Nair R; Chan C-L; Yang J; Foreman N; Fitzpatrick B; Sankaranarayanan G; Law AMK; Ormandy C; Naylor M; McFarland A; Simpson P; Lakhani S; O'Toole S; Selinger C; Anderson L; Samimi G; Hacker N; Kaplan W; Carroll J; Molloy M; Swarbrick A, 2018, 'A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer.', BIORXIV, http://dx.doi.org/10.1101/281196
    Journal articles | 2018
    Holliday H; Baker LA; Junankar SR; Clark SJ; Swarbrick A, 2018, 'Epigenomics of mammary gland development', Breast Cancer Research, 20, http://dx.doi.org/10.1186/s13058-018-1031-x
    Journal articles | 2016
    Baker LA; Holliday H; Swarbrick A, 2016, 'ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer', Endocrine-Related Cancer, 23, pp. R381 - R392, http://dx.doi.org/10.1530/ERC-16-0196
  • Preprints | 2024
    Apostolov E; Roden DL; Holliday H; Cazet A; Harvey K; Zhang H; Wu SZ; van der Leij S; Selth LA; Bartonicek N; Al-Eryani G; He M; Lundeberg J; Reeves J; Kench JG; Potter AJ; Stricker P; Joshua AM; Horvath L; Swarbrick A, 2024, Profiling of epithelial functional states and fibroblast phenotypes in hormone therapy-naïve localised prostate cancer, http://dx.doi.org/10.1101/2024.10.23.619925
    Preprints | 2024
    Holliday H; Khan A; Ehteda A; Ross S; Jayatilleke N; Gopalakrishnan A; Guo X; Liu J; Nguyen H; Lee A; Sanguino YC; Dinger M; Mayoh C; Rayner B; Tsoli M; Ziegler D, 2024, Chromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma, http://dx.doi.org/10.1101/2024.06.06.597703
    Conference Abstracts | 2024
    Holliday H; Khan A; Jayatilleke N; Mayoh C; Ross SE; Guo X; Sanguino YC; Gopalakrishnan A; Ehteda A; Tsoli M; Ziegler DS, 2024, 'COMBINED EPIGENETIC THERAPY WITH FACT AND BET INHIBITORS REMODELS CHROMATIN AND DISRUPTS ONCOGENIC TRANSCRIPTION IN DIFFUSE MIDLINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, PA, Philadelphia, Vol. 26, presented at International Symposium on Pediatric Neuro-Oncology (ISPNO), PA, Philadelphia, 29 June 2024 - 02 July 2024, http://dx.doi.org/10.1093/neuonc/noae064.077
    Conference Abstracts | 2024
    Rayner BS; Samadder A; Holliday H; Chen Y; Nguyen H; Lee A; Liu J; Hayden E; Ogunmodede OS; Rye K-A; Tsoli M; Bertoldo JB; Ziegler DS, 2024, 'THE BIG AND SMALL OF PROTEIN POST-TRANSLATIONAL MODIFICATIONS: TARGETING SUMOYLATION AND CITRULLINATION IN DIFFUSE MIDLINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, PA, Philadelphia, Vol. 26, presented at International Symposium on Pediatric Neuro-Oncology (ISPNO), PA, Philadelphia, 29 June 2024 - 02 July 2024, http://dx.doi.org/10.1093/neuonc/noae064.069
    Preprints | 2023
    Glover H; Holliday H; Shparberg R; Winkler D; Day M; Morris M, 2023, Signalling pathway crosstalk stimulated by L-proline drives differentiation of mouse embryonic stem cells to primitive-ectoderm-like cells, http://dx.doi.org/10.1101/2023.02.14.528585
    Conference Abstracts | 2023
    Holliday H; Khan A; Jayatilleke N; Mayoh C; Ross SE; Sanguino YC; Gopalakrishnan A; Ehteda A; Rayner B; Tsoli M; Ziegler DS, 2023, 'Targeting the epigenome through combined Facilitates Chromatin Transcription (FACT) and Bromodomain and Extra-Terminal Domain (BET) inhibition in Diffuse Midline Glioma (DMG)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MN, Minneapolis, Vol. 84, presented at AACR Special Conference on Brain Cancer, MN, Minneapolis, 19 October 2023 - 22 October 2023, http://dx.doi.org/10.1158/1538-7445.BRAIN23-B016
    Conference Abstracts | 2022
    Holliday H; Ehteda A; Khan A; Krug B; Rouaen JRC; Jayatilleke N; Mayoh C; Vittorio O; Jabado N; Tsoli M; Ziegler DS, 2022, 'DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i18 - i18, http://dx.doi.org/10.1093/neuonc/noac079.063
    Conference Abstracts | 2022
    Holliday H; Ehteda A; Khan A; Krug B; Rouaen JRC; Jayatilleke N; Mayoh C; Vittorio O; Jabado N; Tsoli M; Ziegler DS, 2022, 'UNCOVERING THE FACTS IN DIFFUSE MIDLINE GLIOMA (DMG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 24, pp. 18 - 18, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000840122400065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    Sanguino YC; de la Fuente LR; Kisswani D; Kearney P; Jackson E; Duchatel R; Holliday H; Jabado N; Tsoli M; Ziegler D; Dun M; Mora FV, 2022, 'DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i26 - i27, http://dx.doi.org/10.1093/neuonc/noac079.094
    Conference Abstracts | 2022
    Sanguino YC; de la Fuente LR; Kisswani D; Kearney P; Jackson E; Duchatel R; Holliday H; Jabado N; Tsoli M; Ziegler D; Dun M; Mora FV, 2022, 'EXPLORING THE ROLE OF THE EPIGENETIC FACTOR H2A.Z ACETYLATION IN DIPG', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, GERMANY, Hamburg, Vol. 24, pp. 26 - 27, presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg, 11 June 2022 - 15 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000840122400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints | 2020
    Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v1
    Preprints | 2020
    Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v2
    Preprints | 2019
    Murali R; Varghese BA; Karthikeyan N; Archana PT; Teo WS; McFarland A; Roden DL; Holliday H; Konrad C; Cazet A; Dodson E; George JT; Levine H; Jolly MK; Swarbrick A; Nair R, 2019, Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapy, http://dx.doi.org/10.1101/760686
    Preprints | 2018
    Teo WS; Holliday H; Karthikeyan N; Cazet AS; Roden DL; Harvey K; Konrad CV; Murali R; Varghese BA; P. T. A; Chan C-L; McFarland A; Junankar S; Ye S; Yang J; Nikolic I; Shah JS; Baker LA; Millar EKA; Naylor MJ; Ormandy CJ; Lakhani SR; Kaplan W; Mellick AS; O’Toole SA; Swarbrick A; Nair R, 2018, Id proteins promote a cancer stem cell phenotype in triple negative breast cancer via negative regulation of Robo1, http://dx.doi.org/10.1101/497313

2025 – 2028              Chief Investigator B, Worldwide Cancer Research Grant. GBP£223,610.00. Unlocking The Origin: Deciphering The Critical Role of Neural Progenitor Cells In Pediatric Gliomagenesis

2024 – 2026              Chief Investigator C, Medical Research Future Fund (MRFF) – Early to Mid-Career Researchers Grant. AUD$993,500, (2 years). An immuno-epigenomic approach to identify therapeutic opportunities for Paediatric High-Grade Gliomas

2024 – 2026              Chief Investigator C, The Cure Starts Now and DIPG Collaborative Grant. USD$181,736 (2 years). Targeting post-translational protein modification to halt Diffuse Intrinsic Pontine Glioma tumorgenicity

2024 – 2024              NSW Health and Medical Research Sponsorship Program Grant for the 2024 Kids Cancer Alliance Symposium "Origins of Childhood Cancer". AUD$5,000

2023 – 2026              Cancer Institute New South Wales Early Career Fellowship, valued at AUD$565,523 (3 years). Developing combination therapies with the FACT inhibitor CBL0137 for Diffuse Intrinsic Pontine Glioma (DIPG)

2023 – 2025              Lead CI, Can Too Emerging Leadership Program Project Grant, valued at AUD$200,000 (2 years). Investigating histone citrullination as a novel epigenetic driver in DMG.

2023 – 2024              Lead CI, UNSW Early Career Academic Network (ECAN) Ramaciotti Centre Seed Grant. Valued at AUD$6,000 (1 year). Multifaceted (epi)transcriptome analyses of Diffuse Intrinsic Pontine Glioma (DIPG) using direct RNA sequencing

2023 – 2024              Co-lead CI Three Strohm Sisters Family Foundation Research Grant (New York, USA), valued at USD$5000 (1 year). Dissecting the molecular mechanisms of FACT and H2A.Zac inhibition in DIPG

2022 – 2023              Lead CI, Kid’s Cancer Alliance New Project Grant, valued at AUD$50,000 (1 year). Therapeutic targeting of histone chaperone FACT and BET bromodomain proteins in Diffuse Intrinsic Pontine Glioma (DIPG)

2022                            Prize for runner up ECR oral presentation at the Kids Cancer Alliance Cell Therapies Symposium, 2022, Sydney, Australia, valued at $500

2022                            Travel grant from the Robert Connor Dawes Foundation, valued at $5,000

2021                            Runner up for The Future Impact Award, Children’s Cancer Institute

2020                            Prize for oral presentation at the St Vincent's Campus Post-doc Symposium

2019                            Prize for best rapid-fire talk at Sydney Catalyst International Translational Cancer Research Symposium

2019                            Prize for best rapid-fire talk at Sydney Catalyst Postgraduate and Early Career Researcher Symposium

2018                            Poster prize at Australian Translational Breast Cancer Symposium

2017                            Poster prize at EMBO Advances in Stem Cells and Regenerative Medicine Conference, Heidelberg, Germany

2017                            Prize for best student talk at ANZSCDB NSW Cells and Development Meeting

2017                            Poster prize at Lorne Cancer Conference

2017                            Poster prize at Australian Translational Breast Cancer Symposium

2014 – 2018              Australian Postgraduate Award Scholarship, valued at $25,392 p.a. (3.5 years)

2014 – 2018              UNSW Research Excellence Award, valued at $10,000 p.a. (3.5 years)

2013                            University of Sydney Medal for placing first in cohort

2013                            David J Monk Adams Award for academic excellence in Physiology

2013                            Physiology Honours Scholarship

2012                            Dean’s List for Academic Excellence (High Distinction Average) and University of Sydney Merit Prize

2011                            Dean’s List for Academic Excellence (High Distinction Average) and University of Sydney Merit Prize

2010 – 2013              University of Sydney Access Scholarship, valued at $6,000 p.a. (4 years)

1. Developing combination therapies with the FACT inhibitor CBL0137 for Diffuse Intrinsic Pontine Glioma (DIPG)

2. Investigating histone citrullination as a novel epigenetic driver in DMG

3. Mapping the spatial landscape of paediatric High Grade Glioma's using spatial transcriptomics

4. Exploring the epigenetic and epitranscriptomic mechanisms in DMG

 

 

My Research Supervision

Current students

Co-supervisor of PhD candidate Arjayeeta Samadder. Project: Targeting the post translational modification of citrullination in Diffuse Midline Glioma 

Co-supervisor of PhD candidate Grace Lee. Project: Deciphering the role of Neural Progenitor Cells in paediatric High Grade Glioma

 

Past students

Co-supervisor of Acadia Sivanathan (Honours). Project: Combination therapy with ACT001 and Auranofin in Diffuse Midline Glioma

Co-supervisor of Dr Eva Apostolov (PhD). Project: Cellular genomics analysis in prostate cancer